WO2010086351A1 - 9-déoxo-9a-méthyl-9a-azahomoérythromycine 3'-n-substituée ayant une activité antipaludique - Google Patents

9-déoxo-9a-méthyl-9a-azahomoérythromycine 3'-n-substituée ayant une activité antipaludique Download PDF

Info

Publication number
WO2010086351A1
WO2010086351A1 PCT/EP2010/050969 EP2010050969W WO2010086351A1 WO 2010086351 A1 WO2010086351 A1 WO 2010086351A1 EP 2010050969 W EP2010050969 W EP 2010050969W WO 2010086351 A1 WO2010086351 A1 WO 2010086351A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
methyl
deoxo
aza
Prior art date
Application number
PCT/EP2010/050969
Other languages
English (en)
Inventor
Sulejman Alihodzic
Kristina Starcevic
Original Assignee
Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. filed Critical Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.
Publication of WO2010086351A1 publication Critical patent/WO2010086351A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to novel 3'- ⁇ /-substituted 9-deoxo-9a-methyl-9a-aza-9a- homoerythromycin A derivatives having antimalarial activity. More particularly, the invention relates to 3'- ⁇ /-substituted-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A and 3'- ⁇ /-substituted-3-O-decladinosyl-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A having antimalarial activity, to the intermediates for their preparation, to the methods for their preparation, to their use as therapeutic agents, and to salts thereof having antimalarial activity.
  • Malaria is a serious infection. 200 to 300 million people are infected with malaria and two to three million people die from malaria every year. The disease is caused by a parasite (a protozoa of the Plasmodia genus), which is transmitted by the female Anopheles mosquito. There are four parasites that can affect humans, Plasmodium falciparum, P. vivax, P. ovale, and P. malariae. A distinction is drawn between Malaria tropica (caused by Plasmodium falciparum), Malaria tertiana (caused by Plasmodium vivax or Plasmodium ovale) and Malaria quartana (caused by Plasmodium malariae). Malaria tropica is the most severe form of the disease, and is characterized by severe constitutional symptoms, and sometimes causes death.
  • Malaria is characterized by attacks of chills, fever, and sweating, occurring at intervals which depend on the time required for development of a new generation of parasites in the body. After recovery from the acute attack, the disease has a tendency to become chronic, with occasional relapses. The disease is prevalent in tropical and subtropical areas of the world including the Amazon region of Brazil, East and Southern Africa and Southeast Asia. The emergence of a malaria parasite resistant to chloroquine, which is a drug used extensively in the treatment of malaria, has become a serious problem, and therefore, there is an urgent need to develop an effective remedy. Also, attempts to develop a malaria vaccine have failed to date. This compounds the urgent need to find an alternative drug-based approach to treating malaria.
  • Drugs of diverse chemical classes such as chloroquine, mefloquine, halofantrine, and artemisinin, atovaquone/proguanil (MalaroneTM), doxycycline, and primaquine have been developed for the treatment of malaria.
  • Drugs which worked initially become totally ineffective after a period of time. An initial period of remission is often followed by a period during which nothing seems to be effective against the disease. This is known as multiple drug resistance, and it remains an issue in antimalarial drug development efforts.
  • a malarial parasite which initially responds to treatment by one or more drugs becomes resistant to treatment not only using the drugs previously used, but many other antimalarial drugs. This further underscores the urgent necessity to find new compounds which show good efficacy against malaria and minimal toxicity.
  • the present invention relates to novel 3'- ⁇ /-substituted-9-deoxo-9a-methyl-9a-aza-9a- homoerythromycin A and 3'- ⁇ /-substituted-3-O-decladinosyl-9-deoxo-9a-methyl-9a-aza- 9a-homoerythromycin A derivatives represented by Formula (I):
  • R represents group of Formula (b)
  • R 3 represents H or CH 3 ;
  • R 4 represents -(CH 2 ) a -X-(CH 2 ) b -(NH) c -A, -C(O)-(CH 2 ) b -(NH) c -A or
  • X represents -N(R 5 )-, -NHC(O)- or -C(O)NH- Y represents -N(R 5 )-;
  • R 5 represents H or Ci_ 3 alkyl
  • A is a moiety of Formula (c) or (d):
  • R 6 represents H or halogen and is attached to Formula (c) or (d) at any available carbon atom; a is an integer from 2 to 6; b is an integer from 0 to 6; c is 0 or 1 ; m is an integer from 1 to 4; n is an integer from 1 to 4; provided that when c is 1 then b is an integer from 1 to 6;
  • the present invention also relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the present invention also relates to methods of treating malarial diseases comprising administration of a therapeutically effective amount of a compound of Formula (I) to a patient in need thereof.
  • novel compounds of Formula (I) of the present invention may exhibit good potency against Plasmodia, especially against multiresistant plasmodial species.
  • a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the therapeutic and/or prophylactic treatment of malaria.
  • the treatment is therapeutic or prophylactic treatment.
  • the present invention is also directed to compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof in an amount effective for therapeutic and/or prophylactic treatment of malaria in a subject in need of such treatment.
  • the present invention is also directed to a method for using the compounds of Formula (I) in the prophylaxis of malaria or the treatment of subjects exposed to the malaria parasites.
  • the present invention relates to the novel 3'- ⁇ /-substituted- 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A and 3'- ⁇ /-substituted-3-O- decladinosyl- ⁇ -deoxo- ⁇ a-methyl- ⁇ a-aza- ⁇ a-homoerythromycin A derivatives represented by Formula (I):
  • R 2 represents group of Formula (b)
  • R 3 represents H or CH 3 ;
  • R 4 represents -(CH 2 ) a -X-(CH 2 ) b -(NH) c -A, -C(O)-(CH 2 ) b -(NH) c -A or
  • X represents -N(R 5 )-, -NHC(O)- or -C(O)NH- Y represents -N(R 5 )-;
  • R 5 represents H or d- 3 alkyl
  • A is a moiety of Formula (c) or (d): attached to the rest of the molecule through any available carbon atom;
  • R 6 represents H or halogen and is attached to Formula (c) or (d) at any available carbon atom;
  • a is an integer from 2 to 6;
  • b is an integer from 0 to 6;
  • c is 0 or 1 ;
  • m is an integer from 1 to 4;
  • n is an integer from 1 to 4;
  • b is an integer from 1 to 6;
  • compositions of the invention refers to molecular entities and other ingredients of such compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a mammal (e.g., human).
  • a mammal e.g., human
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in mammals, and more particularly in humans.
  • carrier applied to pharmaceutical compositions of the invention refers to a diluent, excipient, or vehicle with which an active compound is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water, saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E.W. Martin, 18th Edition, incorporated by reference.
  • Particularly preferred for the present invention are carriers suitable for immediate-release, i.e., release of most or all of the active ingredient over a short period of time, such as 60 minutes or less, and make rapid absorption of the drug possible.
  • the compounds of the present invention may be in the form of and/or may be administered as a pharmaceutically acceptable salt.
  • suitable salts see Berge ef a/., J. Pharm. Sci., 66 (1977) 1-19.
  • a pharmaceutical acceptable salt may be readily prepared by using a desired acid.
  • the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
  • an aqueous solution of an acid such as hydrochloric acid may be added to an aqueous suspension of a compound of formula (I) and the resulting mixture evaporated to dryness (lyophilised) to obtain the acid addition salt as a solid.
  • a compound of formula (I) may be dissolved in a suitable solvent, for example an alcohol such as isopropanol, and the acid may be added in the same solvent or another suitable solvent.
  • the resulting acid addition salt may then be precipitated directly, or by addition of a less polar solvent such as diisopropyl ether or hexane, and isolated by filtration.
  • Suitable addition salts are formed from inorganic or organic acids which form non-toxic salts and examples are hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, trifluoroacetate, maleate, malate, fumarate, lactate, tartrate, citrate, formate, gluconate, succinate, pyruvate, oxalate, oxaloacetate, trifluoroacetate, saccharate, benzoate, alkyl or aryl sulphonates (eg methanesulphonate, ethanesulphonate, benzenesulphonate or p-toluenesulphonate) and isethionate.
  • hydrochloride hydrobromide, hydroiodide
  • sulphate bisulphate
  • nitrate phosphate
  • hydrogen phosphate hydrogen phosphate
  • acetate trifluoroa
  • the salt is an acetate salt.
  • Representative examples of salts include trifluoroacetate and formate salts, for example the bis or tris trifluoroacetate salts and the mono or diformate salts, in particular the tris or bis trifluoroacetate salt and the monoformate salt.
  • compounds of the invention are pharmaceutically acceptable salts, solvates and esters. In a further aspect compounds of the invention are pharmaceutically acceptable salts and esters. In a further aspect compounds of the invention are pharmaceutically acceptable salts.
  • solvates complexes with solvents in which they are reacted or from which they are precipitated or crystallized.
  • solvates For example, a complex with water is known as a "hydrate”.
  • Solvates of the compounds of the invention are within the scope of the invention.
  • the salts of the compound of Formula (I) may form solvates (e.g. hydrates) and the invention also includes all such solvates.
  • the present invention also relates to pharmaceutically acceptable esters of the compounds of Formula (I), for example carboxylic acid esters -COOR, in which R is selected from straight or branched chain alkyl, for example n-propyl, n-butyl, alkoxyalkyl
  • any alkyl moiety present in such esters suitably contains 1 to 18 carbon atoms, particularly 1 to 4 carbon atoms. Any aryl moiety present in such esters suitably comprises a phenyl group.
  • references to a compound according to the invention include both compounds of Formula (I), and their pharmaceutically acceptable salts, solvates and esters.
  • the compounds of Formula (I) have more than one asymmetric carbon atom.
  • the solid wedge shaped bond indicates that the bond is above the plane of the paper.
  • the broken bond indicates that the bond is below the plane of the paper.
  • the substituents on the macrolide may also have one or more asymmetric carbon atoms.
  • the compounds of Formula (I) may occur as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof.
  • the present invention includes the individual stereoisomers of the compounds of the invention and, where appropriate, the individual stereoisomeric forms thereof, together with mixtures.
  • Separation of diastereoisomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or HPLC
  • An individual stereoisomer may also be prepared from a corresponding optically pure intermediate or by resolution, such as HPLC, of the corresponding mixture using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding mixture with a suitable optically active acid or base, as appropriate.
  • the compounds of Formula (I) may be in crystalline or amorphous form. Furthermore, some of the crystalline forms of the compounds of Formula (I) may exist as polymorphs, which are included in the present invention.
  • R 1 represents H.
  • R 1 represents an ⁇ -L-cladinosyl group of Formula (a).
  • R 4 represents -(CH 2 ) a -X-(CH 2 ) b -(NH) c -A wherein X is - NHC(O)-, c is 1 , and a, b and A are as defined in Formula (I) above.
  • R 4 represents -(CH 2 ) a -X-(CH 2 ) b -(NH) c -A wherein X is - NHC(O)-, a is 3, b is 3, c is 1 , and A is a moiety of Formula (c).
  • R 4 represents -(CH 2 ) a -X-(CH 2 ) b -(NH) c -A wherein X is -NH-, a is 3, b is 0, c is 0, and A is a moiety of Formula (c).
  • R 4 represents -C(O)-(CH 2 ) b -(NH) c -A wherein b is 3, c is 1 , and A is a moiety of Formula (c).
  • R 4 represents -C(O)-(CH 2 ) b -(NH) c -A wherein b is 1 , c is 1 , and A is a moiety of Formula (c).
  • the sum of a and b is less than or equal to 8. In a further aspect of the invention the sum of a and b is 1 , 3, or 6.
  • a is 3, b is 3 and c is 1. In a further aspect of the invention a is 3, b is 0 and c is 0. In a further aspect of the invention, b is 1 and c is 1. In a further aspect of the invention, b is 3 and c is 1.
  • R 4 represents:
  • N N / ⁇
  • A is a moiety of Formula (c) attached to the rest of the molecule via the 2-, 3-, or 4-position. In a further aspect of the invention, A is a moiety of Formula (d) attached to the rest of the molecule via the 1 -position.
  • A represents 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 7- chloro-4-quinolinyl or 3-chloro-1-isoquinolinyl.
  • A represents 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, or 7-chloro-4-quinolinyl.
  • A represents 4-quinolinyl.
  • A represents 7-chloro-4-quinolinyl.
  • R 5 represents H or methyl. In a further aspect of the invention R 5 represents H.
  • R 6 represents H. In a further aspect of the invention R 6 represents a chlorine atom. In a further aspect of the invention R 6 represents a chlorine atom attached to the moiety of Formula (c) in the 7-position. In a further aspect of the invention R 6 represents a chlorine atom attached to the moiety of Formula (d) in the 3- position.
  • alkyl refers to a saturated, straight or branched-chain hydrocarbon radical containing the stated number of carbon atoms, for example C ⁇ alkyl contains between one and three carbon atoms.
  • Examples of "C ⁇ alkyl” radicals include; methyl, ethyl, propyl, isopropyl.
  • lower alcohol refers to a C ⁇ alcohol, such as for example, methanol, ethanol, propanol, isopropanol, butanol, t-butanol, and the like.
  • halogen refers to a fluorine, chlorine, bromine or iodine atom.
  • inert solvent refers to a solvent that cannot react with the dissolved compounds including non-polar solvent such as hexane, toluene, diethyl ether, diisopropylether, chloroform, ethyl acetate, THF, dichloromethane; polar aprotic solvents such as acetonitrile, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, pyridine, and polar protic solvents such as lower alcohol, acetic acid, formic acid and water.
  • non-polar solvent such as hexane, toluene, diethyl ether, diisopropylether, chloroform, ethyl acetate, THF, dichloromethane
  • polar aprotic solvents such as acetonitrile, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl
  • Compounds of the Formula (I) include:
  • Treating” or “Treatment” of malaria includes therapeutic treatment and prophylactic treatment.
  • “Therapeutic treatment” of malaria includes i. preventing or delaying the appearance of clinical symptoms of malaria developing in a mammal that has been in contact with the parasite, ii. inhibiting the malaria, i.e., arresting, reducing or delaying the development of malaria or a relapse thereof or at least one clinical or subclinical symptom thereof, or iii. relieving or attenuating one or more of the clinical or subclinical symptoms of malaria.
  • the benefit to a subject to be treated is either statistically significant or at least perceptible to the patient or to the physician.
  • “Prophylactic treatment” or “prophylaxis” of malaria includes treating subjects who are at risk of developing malaria. This includes the treatment of subjects who have been exposed to malaria-bearing mosquitoes, the treatment of subjects who intend to travel to a country where malaria is endemic and the treatment of subjects who otherwise risk exposure to malaria-bearing mosquitoes.
  • Mainntenance therapy is preventive therapy that follows successful initial treatment of the acute phase of the illness where regular (usually smaller) doses of the drug are delivered to the patient to prevent recurrence and worsening of the disease.
  • the Plasmodium vivax and P. ovale parasites have dormant liver stages that can remain silent for years. Maintenance therapy for these strains is particularly important.
  • the hallmarks of the acute phase include symptoms like chills and fever.
  • Subject refers to an animal, in particular a mammal and more particularly to a human or a domestic animal or an animal serving as a model for a disease (e.g., mouse, monkey, etc.).
  • the subject is a human.
  • patient is used synonymously with subject.
  • a “therapeutically effective amount” means the amount of a compound that, when administered to a mammal for treating a state, disorder or condition, is sufficient to effect such treatment.
  • the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the mammal to be treated and will be ultimately at the discretion of the attendant physician.
  • a compound of Formula (I) may be administered as the bulk substance, it is preferable to present the active ingredient in a pharmaceutical formulation, for example, wherein the agent is in admixture with at least one pharmaceutically acceptable carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • carrier refers to a diluent, excipient, and/or vehicle with which an active compound is administered.
  • the pharmaceutical compositions of the invention may contain combinations of more than one carrier.
  • Such pharmaceutical carriers can be sterile liquids, such as water, saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W.
  • compositions may comprise as, in addition to, the carrier any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilizing agent(s).
  • a “pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes an excipient that is acceptable for veterinary use as well as human pharmaceutical use.
  • pharmaceutically acceptable excipient as used in the present application includes both one and more than one such excipient.
  • compositions for use in accordance with the present invention may be in the form of oral, parenteral, transdermal, inhalation, sublingual, topical, implant, nasal, or enterally administered (or other mucosally administered) suspensions, capsules or tablets, which may be formulated in conventional manner using one or more pharmaceutically acceptable carriers or excipients.
  • composition/formulation requirements depending on the different delivery systems. It is to be understood that not all of the compounds need to be administered by the same route. Likewise, if the composition comprises more than one active component, then those components may be administered by the same or different routes.
  • the pharmaceutical composition of the present invention may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestible solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may be designed to be delivered by multiple routes.
  • the present invention further relates to pharmaceutical formulations containing a therapeutically effective quantity of a compound of Formula (I) or one of its salts mixed with a pharmaceutically acceptable vehicle.
  • the pharmaceutical formulations of the present invention can be liquids that are suitable for oral, mucosal and/or parenteral administration, for example, drops, syrups, solutions, injectable solutions that are ready for use or are prepared by the dilution of a freeze-dried product but are preferably solid or semisolid as tablets, capsules, granules, powders, pellets, pessaries, suppositories, creams, salves, gels, ointments; or solutions, suspensions, emulsions, or other forms suitable for administration by the transdermal route or by inhalation.
  • the compounds of the invention can be administered for immediate-, delayed-, modified-, sustained-, pulsed-or controlled-release applications.
  • oral compositions are slow, delayed or positioned release (e.g., enteric especially colonic release) tablets or capsules.
  • This release profile can be achieved without limitation by use of a coating resistant to conditions within the stomach but releasing the contents in the colon or other portion of the Gl tract wherein a lesion or inflammation site has been identified.
  • a delayed release can be achieved by a coating that is simply slow to disintegrate.
  • the two (delayed and positioned release) profiles can be combined in a single formulation by choice of one or more appropriate coatings and other excipients. Such formulations constitute a further feature of the present invention.
  • Suitable compositions for delayed or positioned release and/or enteric coated oral formulations include tablet formulations film coated with materials that are water resistant, pH sensitive, digested or emulsified by intestinal juices or sloughed off at a slow but regular rate when moistened.
  • Suitable coating materials include, but are not limited to, hydroxypropyl methylcellulose, ethyl cellulose, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, polymers of metacrylic acid and its esters, and combinations thereof.
  • Plasticizers such as, but not limited to polyethylene glycol, dibutylphthalate, triacetin and castor oil may be used.
  • a pigment may also be used to color the film.
  • Suppositories are be prepared by using carriers like cocoa butter, suppository bases such as Suppocire C, and Suppocire NA50 (supplied by Gattefosse GmbH, D-Weil am Rhein, Germany) and other Suppocire type excipients obtained by interesterification of hydrogenated palm oil and palm kernel oil (Cede triglycerides), esterification of glycerol and specific fatty acids, or polyglycosylated glycerides, and whitepsol (hydrogenated plant oils derivatives with additives).
  • Enemas are formulated by using the appropriate active compound according to the present invention and solvents or excipients for suspensions.
  • Suspensions are produced by using micronized compounds, and appropriate vehicle containing suspension stabilizing agents, thickeners and emulsifiers like carboxymethylcellulose and salts thereof, polyacrylic acid and salts thereof, carboxyvinyl polymers and salts thereof, alginic acid and salts thereof, propylene glycol alginate, chitosan, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, ethylcellulose, methylcellulose, polyvinyl alcohol, polyvinyl pyrrolidone, N-vinylacetamide polymer, polyvinyl methacrylate, polyethylene glycol, pluronic, gelatin, methyl vinyl ether-maleic anhydride copolymer, soluble starch, pullulan and a copolymer of methyl acrylate and 2-ethylhexyl acrylate lecithin, lecithin derivatives, propylene glycol fatty acid esters, glycerin fatty acid esters
  • materials may be incorporated into the matrix of the tablet e.g. hydroxypropyl methylcellulose, ethyl cellulose or polymers of acrylic and metacrylic acid esters. These latter materials may also be applied to tablets by compression coating.
  • compositions can be prepared by mixing a therapeutically effective amount of the active substance with a pharmaceutically acceptable carrier that can have different forms, depending on the way of administration.
  • Pharmaceutical compositions can be prepared by using conventional pharmaceutical excipients and methods of preparation.
  • the forms for oral administration can be capsules, powders or tablets where usual solid vehicles including lactose, starch, glucose, methylcellulose, magnesium stearate, di- calcium phosphate, mannitol may be added, as well as usual liquid oral excipients including, but not limited to, ethanol, glycerol, and water. All excipients may be mixed with disintegrating agents, solvents, granulating agents, moisturizers and binders.
  • compositions e.g., starch, sugar, kaolin, binders disintegrating agents
  • preparation can be in the form of powder, capsules containing granules or coated particles, tablets, hard gelatin capsules, or granules without limitation, and the amount of the solid carrier can vary (between 1 mg to 1g). Tablets and capsules are the preferred oral composition forms.
  • compositions containing compounds of the present invention may be in any form suitable for the intended method of administration, including, for example, a solution, a suspension, or an emulsion.
  • Liquid carriers are typically used in preparing solutions, suspensions, and emulsions.
  • Liquid carriers contemplated for use in the practice of the present invention include, for example, water, saline, pharmaceutically acceptable organic solvent(s), pharmaceutically acceptable oils or fats, and the like, as well as mixtures of two or more thereof.
  • the liquid carrier may contain other suitable pharmaceutically acceptable additives such as solubilizers, emulsifiers, nutrients, buffers, preservatives, suspending agents, thickening agents, viscosity regulators, stabilizers, and the like.
  • Suitable organic solvents include, for example, monohydric alcohols, such as ethanol, and polyhydric alcohols, such as glycols.
  • Suitable oils include, for example, soybean oil, coconut oil, olive oil, safflower oil, cottonseed oil, and the like.
  • the carrier can also be an oily ester such as ethyl oleate, isopropyl myristate, and the like.
  • Compositions of the present invention may also be in the form of microparticles, microcapsules, liposomal encapsulates, and the like, as well as combinations of any two or more thereof.
  • Examples of pharmaceutically acceptable disintegrants for oral compositions useful in the present invention include, but are not limited to, starch, pre-gelatinized starch, sodium starch glycolate, sodium carboxymethylcellulose, croscarmellose sodium, microcrystalline cellulose, alginates, resins, surfactants, effervescent compositions, aqueous aluminum silicates and crosslinked polyvinylpyrrolidone.
  • binders for oral compositions useful herein include, but are not limited to, acacia; cellulose derivatives, such as methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose or hydroxyethylcellulose; gelatin, glucose, dextrose, xylitol, polymethacrylates, polyvinylpyrrolidone, sorbitol, starch, pre-gelatinized starch, tragacanth, xanthane resin, alginates, magnesium-aluminum silicate, polyethylene glycol or bentonite.
  • acacia cellulose derivatives, such as methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose or hydroxyethylcellulose
  • gelatin glucose, dextrose, xylitol, polymethacrylates, polyvinylpyrrolidone, sorbitol, starch, pre-gelatinized starch, tragacanth, xanthane
  • Examples of pharmaceutically acceptable fillers for oral compositions include, but are not limited to, lactose, anhydrolactose, lactose monohydrate, sucrose, dextrose, mannitol, sorbitol, starch, cellulose (particularly microcrystalline cellulose), dihydro- or anhydro- calcium phosphate, calcium carbonate and calcium sulfate.
  • Examples of pharmaceutically acceptable lubricants useful in the compositions of the invention include, but are not limited to, magnesium stearate, talc, polyethylene glycol, polymers of ethylene oxide, sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, and colloidal silicon dioxide.
  • Suitable pharmaceutically acceptable odorants for the oral compositions include, but are not limited to, synthetic aromas and natural aromatic oils such as extracts of oils, flowers, fruits (e.g., banana, apple, sour cherry, peach) and combinations thereof, and similar aromas. Their use depends on many factors, the most important being the organoleptic acceptability for the population that will be taking the pharmaceutical compositions.
  • suitable pharmaceutically acceptable dyes for the oral compositions include, but are not limited to, synthetic and natural dyes such as titanium dioxide, beta-carotene and extracts of grapefruit peel.
  • Suitable examples of pharmaceutically acceptable sweeteners for the oral compositions include, but are not limited to, aspartame, saccharin, saccharin sodium, sodium cyclamate, xylitol, mannitol, sorbitol, lactose and sucrose.
  • Suitable examples of pharmaceutically acceptable buffers include, but are not limited to, citric acid, sodium citrate, sodium bicarbonate, dibasic sodium phosphate, magnesium oxide, calcium carbonate and magnesium hydroxide.
  • Suitable examples of pharmaceutically acceptable surfactants include, but are not limited to, sodium lauryl sulfate and polysorbates.
  • Suitable examples of pharmaceutically acceptable preservatives include, but are not limited to, various antibacterial and antifungal agents such as solvents, for example ethanol, propylene glycol, benzyl alcohol, chlorobutanol, quaternary ammonium salts, and parabens (such as methyl paraben, ethyl paraben, propyl paraben, etc.).
  • suitable examples of pharmaceutically acceptable stabilizers and antioxidants include, but are not limited to, ethylenediaminetetriacetic acid (EDTA), thiourea, tocopherol and butyl hydroxyanisole.
  • the compounds of the invention may also, for example, be formulated as suppositories e.g., containing conventional suppository bases for use in human or veterinary medicine or as pessaries e.g., containing conventional pessary bases.
  • the compounds according to the invention may be formulated for topical administration, for use in human and veterinary medicine, in the form of ointments, creams, gels, hydrogels, lotions, solutions, shampoos, powders (including spray or dusting powders), pessaries, tampons, sprays, dips, aerosols, drops (e.g., eye ear or nose drops) or pour- ons.
  • the agent of the present invention can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.
  • Such compositions may also contain other pharmaceutically acceptable excipients, such as polymers, oils, liquid carriers, surfactants, buffers, preservatives, stabilizers, antioxidants, moisturizers, emollients, colorants, and odorants.
  • Examples of pharmaceutically acceptable polymers suitable for such topical compositions include, but are not limited to, acrylic polymers; cellulose derivatives, such as carboxymethylcellulose sodium, methylcellulose or hydroxypropylcellulose; natural polymers, such as alginates, tragacanth, pectin, xanthan and cytosan.
  • the compound of the present invention can be administered intranasally or by inhalation and is conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray or nebulizer with the use of a suitable propellant, e.g., a hydrofluoroalkane such as 1 ,1 ,1 ,2- tetrafluoroethane (HFA 134AT) or 1 , 1 ,1 , 2,3,3, 3-heptafluoropropane (HFA 227EA), or a mixture thereof.
  • a suitable propellant e.g., a hydrofluoroalkane such as 1 ,1 ,1 ,2- tetrafluoroethane (HFA 134AT) or 1 , 1 ,1 , 2,3,3, 3-heptafluoropropane (HFA 227EA), or a mixture thereof.
  • the dosage unit may be determined by providing a valve to deliver a me
  • the pressurized container, pump, spray or nebulizer may contain a solution or suspension of the active compound, e.g., using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g., sorbitan trioleate.
  • a lubricant e.g., sorbitan trioleate.
  • Capsules and cartridges made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the compounds according to the invention may be delivered for use in human or veterinary medicine via a nebulizer.
  • compositions of the invention may contain from 0.01 to 99% weight per volume of the active material.
  • the composition will generally contain from 0.01-10%, more preferably 0.01-1 % of the active material.
  • a therapeutically effective amount of the compound of the present invention can be determined by methods known in the art.
  • the therapeutically effective quantities will depend on the age and on the general physiological condition of the subject, the route of administration and the pharmaceutical formulation used.
  • the therapeutic doses will generally be between about 10 and 2000 mg/day and suitably between about 30 and 1500 mg/day. Other ranges may be used, including, for example, 50-500 mg/day, 50-300 mg/day, 20-200 mg/day, 100-200 mg/day.
  • the daily dose as employed for adult human treatment will range from 0.01 to 250 mg/kg body weight, suitably 2-100 mg/kg body weight, or suitably 5-60 mg/kg body weight, which may be administered in one to four daily doses, for example, depending on the route of administration and the condition of the subject.
  • each unit will generally contain 10 mg to 2 g of active ingredient, suitably 200 mg to 1 g of active ingredient.
  • the amount of the compound required for prophylactic treatment referred to as a prophylactically- effective dosage, is generally the same as described for therapeutic treatment although it may be desirable to use a smaller dose and/or less frequent dosing, such as once per week.
  • Administration may be once a day, twice a day, or more often, and may be decreased during a maintenance phase of the disease or disorder, e.g. once every second or third day instead of every day or twice a day.
  • the dose and the administration frequency will depend on the clinical signs, which confirm maintenance of the remission phase, with the reduction or absence of at least one or more preferably more than one clinical signs of the acute phase known to the person skilled in the art.
  • protected derivatives of intermediates used in the preparation of the compounds of Formula (I). Protection and deprotection of functional groups may be performed by methods known in the art. Hydroxyl or amino groups may be protected with any hydroxyl or amino protecting group (for example, as described in Green and Wuts. Protective Groups in Organic Synthesis. John Wiley and Sons, New York, 1999). The protecting groups may be removed by conventional techniques. For example, acyl groups (such as alkanoyl, alkoxycarbonyl and aryloyl groups) may be removed by solvolysis (e.g., by hydrolysis under acidic or basic conditions).
  • Arylmethoxycarbonyl groups may be cleaved by hydrogenolysis in the presence of a catalyst such as palladium-on- carbon.
  • 1 ,2 diol groups may be protected as acetal by reaction with dimethyl acetal of N,N-dimethylacetamide (DMADMA) or dimethyl acetal of N,N-dimethylformamide (DMFDMA) which may be removed by hydrogenolysis or methanolisis at reflux ⁇ Tetrahedron Lett. 12 (1971 ), 813-816, Collection Czech. Chem. Commun. 32 (1967), 3159).
  • DMADMA dimethyl acetal of N,N-dimethylacetamide
  • DMFDMA dimethyl acetal of N,N-dimethylformamide
  • the synthesis of the target compound is completed by removing any protecting groups, which are present in the penultimate intermediate using standard techniques, which are well-known to those skilled in the art.
  • the final product is then purified, as necessary, using standard techniques such as silica gel chromatography, HPLC on silica gel, and the like or by recrystallization.
  • the reductive amination reaction is preferably carried out in a solvent such as methanol, DMF or a mixture thereof.
  • a suitable reducing agent is, for example sodium cyanoborohydride.
  • Compounds of Formula (I) wherein R 1 is a group of Formula a), X is divalent radical -N(R 5 )-, a is 2-6, b is 0, and c is 0, may be prepared by reaction of an amine of Formula (II) with a reagent of Formula (IV)
  • Leaving group L may be any leaving group known in the art to be suitable for this type of reaction.
  • L is selected from chloride, bromide, iodide, tosyloxy and methanesulfonyloxy group.
  • the reaction is preferably carried out in a solvent such as a halohydrocarbon (e.g. dichloromethane), an ether (e.g. tetrahydrofuran or dimethoxyethane), acetonitrile or ethyl acetate and the like, dimethylsulfoxide, N,N-dimethylformamide or 1-methyl-pyrrolidone and in the presence of a base, followed, if desired, by removal of the hydroxyl protecting groups.
  • a solvent such as a halohydrocarbon (e.g. dichloromethane), an ether (e.g. tetrahydrofuran or dimethoxyethane), acetonitrile or ethyl acetate and the like, dimethylsulfoxide, N,N-dimethylformamide or 1-methyl-pyrrolidone and in the presence of a base, followed, if desired, by removal of the hydroxyl protecting groups.
  • Suitable bases include organic bases such as diisopropylethylamine, triethylamine and 1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU), and inorganic bases such as potassium hydroxide, cesium hydroxide, tetraalkylammonium hydroxide, sodium hydride, potassium hydride and the like.
  • organic bases such as diisopropylethylamine, triethylamine and 1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU)
  • inorganic bases such as potassium hydroxide, cesium hydroxide, tetraalkylammonium hydroxide, sodium hydride, potassium hydride and the like.
  • L represents leaving group under reaction conditions as described above for compounds of Formula (II) and (IV).
  • Leaving group L may be any leaving group known in the art to be suitable for this type of reaction.
  • L is selected from chloride, bromide, iodide, tosyloxy and methanesulfonyloxy group.
  • carbodiimides such as dicyclohexylcarbodiimide (DCC), 1 ,8- diazabicyclo[5.4.0.]undec-7-ene (DBU) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) in the presence of hydroxybenzotriazole monohydrate (HOBt) in a suitable aprotic solvent such as a halohydrocarbon (e.g. dichloromethane) or N,N-dimethylformamide optionally in the presence of a tertiary organic base such as dimethylaminopyridine or triethylamine or in the presence of an inorganic base (eg.
  • DCC dicyclohexylcarbodiimide
  • DBU 1 ,8- diazabicyclo[5.4.0.]undec-7-ene
  • EDC 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
  • compounds of Formula (I), wherein R 1 is a group of Formula a), X is divalent radical -C(O)NH-, a is 2-6, b is 0-6, and c is 0, may be prepared by reaction of a compound of Formula (VII) wherein R 7 is H or hydroxyl protecting group
  • the reaction is suitably carried out in a suitable inert solvent such as halohydrocarbon (e.g. dichloromethane) or N,N-dimethylformamide, lower alcohol (e.g. tert-butanol, iso- propanol, ethanol or methanol) optionally in the presence of EDC, an organic base such as dimethylaminopyridine, triethylamine or DBU, or an inorganic base such as sodium hydroxide, lithium hydroxide or potassium hydroxide, and at a temperature within the range 0° to 120 0 C.
  • a suitable inert solvent such as halohydrocarbon (e.g. dichloromethane) or N,N-dimethylformamide, lower alcohol (e.g. tert-butanol, iso- propanol, ethanol or methanol)
  • EDC organic base
  • dimethylaminopyridine triethylamine or DBU
  • an inorganic base such as sodium hydrox
  • compounds of Formula (I) wherein R 1 is a group of Formula a), X is divalent radical -N(R 5 )-, a is 2-6, b is 1-6, and c is 1 may be prepared by reaction of a compound of Formula (II) wherein R 7 is H or hydroxyl protecting group, with a suitable aldehyde of Formula (IX)
  • compounds of Formula (I) wherein R 1 is a group of Formula a), X is divalent radical -NHC(O)-, a is 2-6, b is 1-6, and c is 1 may be prepared by reaction of a compound of Formula (II compound of Formula (X) in the presence of carbodiimides such as dicyclohexylcarbodiimide (DCC), 1 ,8- diazabicyclo[5.4.0.]undec-7-ene (DBU) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), in the presence of hydroxybenzotriazole monohydrate (HOBt) in a suitable aprotic solvent such as a halohydrocarbon (e.g.
  • dichloromethane or N,N-dimethylformamide, optionally in the presence of a tertiary organic base such as dimethylaminopyridine or triethylamine or in the presence of an inorganic base (eg. sodium hydroxide), and at a temperature within the range 0° to 120 0 C.
  • a tertiary organic base such as dimethylaminopyridine or triethylamine
  • an inorganic base eg. sodium hydroxide
  • compounds of Formula (I) wherein R 1 is a group of Formula a), X is divalent radical -C(O)NH-, a is 2-6, b is 1-6, and c is 1 may be prepared by reaction of a compound of Formula (VII) wherein wherein R 7 is H or hydroxyl protecting group, with compound of Formula (Xl)
  • the reaction is suitably carried out in a suitable inert solvent such as a halohydrocarbon (e.g. dichloromethane) or N,N-dimethylformamide, lower alcohol (e.g. tert-butanol, iso- propanol, ethanol or methanol), optionally in the presence of EDC, an organic base such as dimethylaminopyridine, triethylamine or DBU, or an inorganic base such as sodium hydroxide, lithium hydroxide or potassium hydroxide, and at a temperature within the range 0° to 120 0 C.
  • a suitable inert solvent such as a halohydrocarbon (e.g. dichloromethane) or N,N-dimethylformamide, lower alcohol (e.g. tert-butanol, iso- propanol, ethanol or methanol), optionally in the presence of EDC, an organic base such as dimethylaminopyridine, triethylamine or DBU,
  • the reaction is suitably carried out in a suitable solvent such as acetic acid using suitable reduction conditions, such as hydrogenation in the presence of a suitable catalyst such as platinum dioxide at a suitable pressure, such as 5 barr.
  • a suitable solvent such as acetic acid
  • suitable reduction conditions such as hydrogenation
  • a suitable catalyst such as platinum dioxide
  • a suitable vinyl nitrile for example acrylonitrile in the case where a' is 2, in the presence of a strong base, such as NaOH, KO ⁇ Bu, NaO*Bu or NaH, in a suitable solvent such as DMSO or t-BuOH.
  • a strong base such as NaOH, KO ⁇ Bu, NaO*Bu or NaH
  • a suitable solvent such as DMSO or t-BuOH.
  • Compounds of Formula (XII) wherein a' is 1 may be prepared from compounds of Formula (XIII), wherein R 7 is a suitable hydroxy protecting group, by reaction with a suitable monohalogenated acetonitrile, for example chloracetonitrile, in the presence of a strong base, such as NaOH, KO ⁇ Bu, NaO*Bu or NaH, in a suitable solvent such as DMSO or t- BuOH.
  • a suitable monohalogenated acetonitrile for example chloracetonitrile
  • a strong base such as NaOH, KO ⁇ Bu, NaO*Bu or NaH
  • R 7 is a suitable hydroxy protecting group, by reaction with a compound of Formula (XV) wherein a" is an integer of 1 or 2, under conditions of Grubbs metathesis (A.K. Chatterjee, T.-L. Choi, DP. Sanders, R.H. Grubbs, JACS 125 (2003) 1 1360). Selective reduction of the double bond (and not the -CN group) may be achieved by hydrogenation in the presence of Pd/C catalyst in a suitable solvent, such as an alcohol such as ethanol or methanol ⁇ J. Med. Chem 51 (2008) 424-431).
  • a suitable solvent such as an alcohol such as ethanol or methanol
  • Compounds of Formula (II) wherein a is an integer of 5 or 6 may also be prepared from compounds of Formula (XIV) and (XV) using Grubbs metathesis as described above, but using acidic reduction conditions such as hydrogenation in the presence of a suitable catalyst such as platinum dioxide at a suitable pressure, such as 5 barr, in a suitable solvent such as acetic acid.
  • Compounds of Formula (XIV) may be prepared by palladium-catalysed allylation of compounds of Formula (XIII), for example according to the procedure described in WO 2006/120541 for Intermediate 16.
  • Compounds of formula (VII) wherein R 7 is a suitable hydroxy protecting group and a is 2 may be prepared by reaction of a compound of Formula (XIII) with methyl acrylate in the presence of a strong base, such as NaOH, KOtBu, NaOtBu or NaH, in a suitable solvent such as DMSO or t-BuOH, followed by ester hydrolysis under conditions well known to those skilled in the art.
  • a strong base such as NaOH, KOtBu, NaOtBu or NaH
  • Compounds of Formula (VII) in which a is an integer of 2 to 6 may be prepared by hydrolysis of a compound of Formula (XII) in which a' is an integer of 2 to 6.
  • a' is an integer from 2 to 6.
  • (XVI) a' 4
  • Compounds of Formula (VII) in which a is an integer from 4 to 6 may be prepared by reduction of a compound of Formula (XVI) in which a' is an integer from 3 to 5, for example using sodium borohydride to yield an alcohol intermediate, followed by halogenation, for example using SOCI 2 , followed by Grignard reaction, for example using magnesium in the presence of CO 2 .
  • irradiating for example using a 500W lamp, in the presence of a suitable halogen such as iodine or bromine, in the presence of a suitable base such as sodium acetate, and in a suitable inert solvent (one which will dissolve the reactants at least partially and yet not react with them) such as methanol, THF, DMF or dioxane or by reaction with Triphenylphosphine-Diethyl Azodicarboxylate (DEAD) in acetone followed by hydrolyzation of formed adduct in mixture of methanol and saturated ammonium chloride solution.
  • a suitable halogen such as iodine or bromine
  • a suitable base such as sodium acetate
  • a suitable inert solvent one which will dissolve the reactants at least partially and yet not react with them
  • Compounds of Formula (XVI) wherein a' is 2 to 6 may be prepared from compounds of Formula (VII) wherein a is 2 to 6, by reduction with DIBAI-H (diisobutylaluminium hydride) in dry THF at a low temperature, suitably around -78 0 C.
  • DIBAI-H diisobutylaluminium hydride
  • a suitable copper (I) catalyst for example formed in situ by reduction of a copper (II) salt, such as copper (II) sulfate pentahydrate, with a suitable reducing agent such as sodium ascorbate, in a suitable solvent such as a mixture of DMF and water.
  • Compounds of Formula (XVIII) may be prepared from compounds of Formula (XIII) by reaction with a compound of Formula (XX) L-(CH 2 ) m - ⁇ (XX)
  • L is a suitable leaving group such as bromide
  • a suitable solvent such as THF.
  • An example of a suitable compounds of Formula (XX) is propargylbromide.
  • L is a suitable leaving group such as chloro, with a suitable amino alcohol of Formula HO-(CH 2 ) n -NH 2 .
  • Compounds of Formula (I) wherein R 4 is -C(O)-(CH 2 ) b -(NH) c -A, b is 0-6 and c is 0 may be prepared by reaction of an amine of Formula XIII wherein R 7 is H or hydroxyl protecting group, with a compound of Formula (Vl) in the presence of carbodiimides such as dicyclohexylcarbodiimide (DCC), 1 ,8- diazabicyclo[5.4.0.]undec-7-ene (DBU) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) in the presence of hydroxybenzotriazole monohydrate (HOBt) in a suitable aprotic solvent such as a halohydrocarbon (e.g.
  • dichloromethane or N,N-dimethylformamide optionally in the presence of a tertiary organic base such as dimethylaminopyridine or triethylamine or in the presence of an inorganic base (eg. sodium hydroxide) and at a temperature within the range 0° to 12O 0 C.
  • a tertiary organic base such as dimethylaminopyridine or triethylamine
  • an inorganic base eg. sodium hydroxide
  • carbodiimides such as dicyclohexylcarbodiimide (DCC), 1 ,8- diazabicyclo[5.4.0.]undec-7-ene (DBU) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) in the presence of hydroxybenzotriazole monohydrate (HOBt) in a suitable aprotic solvent such as a halohydrocarbon (e.g. dichloromethane) or N,N-dimethylformamide optionally in the presence of a tertiary organic base such as dimethylaminopyridine or triethylamine or in the presence of an inorganic base (eg. sodium hydroxide) and at a temperature within the range 0° to 12O 0 C.
  • carbodiimides such as dicyclohexylcarbodiimide (DCC), 1 ,8- diazabicyclo[5.4.0.]undec-7-ene (D
  • Compounds of Formula (I) wherein R 1 is hydrogen may be prepared by acid hydrolysis with diluted hydrochloric acid of compound of Formula (I) wherein R 1 is a group of Formula (a) at a temperature within the range 20° to 4O 0 C.
  • Compounds of Formula (I) wherein R 5 is Ci_ 3 alkyl may be prepared by alkylation of compounds of Formula (I) wherein R 5 is hydrogen, for example where R 5 is methyl by alkylating a chloroform solution of the compound wherein R 5 is hydrogen with formaldehyde in the presence of formic acid.
  • Compounds of Formula (I) wherein A is a compound of Formula (c) or (d) and R 6 is hydrogen may be prepared by hydrogenation of the corresponding compound of Formula (I) wherein R 6 is chlorine, for example by exposure to a hydrogen atmosphere in the presence of 10% Pd/C catalyst.
  • Salts such as pharmaceutically acceptable acid addition salts, which also represent an object of the present invention, may be obtained by reaction of a compound of Formula (I) with an at least equimolar amount of the corresponding inorganic or organic acid such as hydrochloric acid, hydroiodic acid, sulfuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, propionic acid, benzoic acid, benzenesulfonic acid, methane sulfonic acid, laurylsulfonic acid, stearic acid, palmitic acid, succinic acid, ethylsuccinic acid, lactobionic acid, oxalic acid, salicylic acid and similar acid, in a solvent inert to the reaction.
  • Addition salts are isolated by evaporating the solvent or, alternatively, by filtration after a spontaneous precipitation or a precipitation by the addition of a non-polar cosolvent.
  • the culture medium comprised RPMI 1640 with 25mM HEPES, sodium bicarbonate and glutamine (GIBCOTM cat. ref.: 52400), supplemented with 10% of pooled human sera AB
  • This culture medium (“complete medium”) was usually prepared fresh just before use and pre-warmed to 37 0 C.
  • Red blood cells AB- stock suspensions were prepared from whole blood bags coming from incomplete blood donation, provided by the Spanish Red Cross ( ⁇ 25 days after sampling). This "whole blood” was aliquoted and stored at 4 0 C.
  • red blood cells for the assay, the whole blood was centrifuged and washed 3 times with RPMI without serum. The upper phase, containing white blood cells was removed. The washed red blood cells were kept as a 50 % suspension in complete medium. The prepared cells were stored at 4 0 C and were employed in the assay at any time up to 4 days after preparation.
  • Test compounds were dissolved at 2 mg/ml in 100% DMSO on the day of the assay. If necessary, complete dissolution was achieved by gentle heating (the mixture was heated at a temperature ⁇ 37°C) and sonication (sonication bath).
  • the percentage of DMSO in the compound solution was reduced by further dilutions of the solution with culture medium prepared in the same way as described above for complete medium, but which did not contain hypoxanthine.
  • the final concentration of DMSO in the assay plates was not permitted to exceed 0.2%, so that it did not produce any detectable undesired effects on the development of the parasite.
  • 10 serial 2-fold dilutions were prepared in complete medium in the presence of a constant amount of DMSO. Any obvious signs of insolubility of the stock solutions in 100% DMSO or precipitation when these solutions were diluted in assay media, were recorded.
  • Plasmodium falciparum strains were maintained in complete medium at an hematocrit of
  • the parasitemia was calculated by counting the percentage of parasitized erythrocytes by optical microscopy. Thin films of blood were made every day from each culture flask, fixed with methanol and stained for 10 min. in Giemsa (Merck, cat. ref.: 1.09204) at 10 % in buffered water pH 7.2. The glass slides were observed and counted with an optical microscope (Nikon, Eclipse E200) equipped with a 100 X immersion oil objective.
  • the culture was maintained at an hematocrit of 5%, with a daily change of medium and was diluted when parasitemia had reached about 5%.
  • test compounds 50 ⁇ l of a 5X solution / well
  • Compounds of this invention (Table 1 ) were tested in this assay. Chloroquine and Azithromycin were used as control compounds for each assay.
  • the inoculum was prepared as a suspension of parasitized red blood cells (PRBCs) at 2.5% of hematocrit and 0.5% of parasitemia in culture medium prepared in the same way as described above for complete medium, but which did not contain hypoxanthine.
  • PRBCs parasitized red blood cells
  • [ 3 H]-Hypoxanthine (Amersham Biosciences, cat. ref.: TRK74) was added extemporaneously to the inoculum suspension at a concentration of 1 ⁇ Ci/ml (equating to 0.25 ⁇ Ci /well). 200 ⁇ l of the resulting suspension was distributed into each well (other than the control well H12 described below) leading to a final volume of 250 ⁇ l per well, at 1 % of hematocrit and 0.4 % of parasitemia / well.
  • A12-D12- Background value wells Uninfected RBCs - blank control to obtain the background reading from RBCs without parasites.
  • E12-G12- Solvent effect wells PRBCs without DMSO - to determine DMSO solvent effect on PRBCs by comparing these wells with column 1 1 wells.
  • Y ⁇ M-Non-radioactive well PRBCs with cold hypoxanthine - (i) to carry out a thin blood film to determine parasitemia value after incubation by microscopy and (ii) to ensure that the parasites have grown properly during the assay.
  • 200 ⁇ l of inoculum suspension was prepared as described above (Items 2 and 3) but with non-tritiated hypoxanthine instead of [ 3 H]-hypoxanthine, then added to this well to a final volume of 250 ⁇ l).
  • the filters were dried and treated with a Melt-on scintillator (Meltilex ® A, PerkinElmer cat. ref.: 1450-441 ). Incorporation of radioactivity was measured with a ⁇ -counter (Wallac Microbeta, PerkinElmer).
  • the assays were repeated at least three independent times.
  • non-linear regression fit sigmoid dose-response curve
  • GaphPad Prism 4.0 software is adjusted to obtain an IC 50 value, corresponding to the concentration which inhibits 50% of parasite development.
  • Results were expressed as the average IC 50 value + standard deviation of at least 3 independent experiments performed on different days.
  • 9a-methyl-9a-aza-9-deoxo-9a-homoerythromycin A may be prepared by the procedure as described in J. Chem. Res. (S) 1988, p152.
  • Step 2 Preparation of 3'-( ⁇ /-demethyl)-3'- ⁇ /-( ⁇ -cyanoethyl)-9-deoxo-9a-methyl-9a-aza- 9a-homoerythromycin A
  • Step 3 Preparation of 3'-( ⁇ /-demethyl)-3'- ⁇ /-( ⁇ -aminopropyl)-9-deoxo-9a-methyl-9a- aza-9a-homoerythromycin A
  • Step 1 Preparation of S-O-decladinosyl- ⁇ -deoxo- ⁇ a-methyl- ⁇ a-aza- ⁇ a- homoerythromycin A
  • ⁇ -Deoxo- ⁇ a-methyl- ⁇ a-aza- ⁇ a-homoerythromycin A (10 g, 0.013 mol) was dissolved in methanol (100 ml) and water (50 ml) and pH was adjusted to 1.79 with 2N HCI. The reaction mixture was stirred at r.t. 24 h. After 24 hours the reaction mixture was stirred at 5O 0 C for 4 hours and 30 minutes. Then the reaction mixture was stirred at r.t. for next 24 h. The methanol was evaporated. DCM (50 ml) was added, pH adjusted to 1.79 and layers separated (3 times).
  • Step 2 Preparation of 3'- ⁇ /-(demethyl)-3-O-decladinosyl-9-deoxo-9a-methyl-9a-aza- 9a-homoerythromycin A
  • Step 3 Preparation of 3'- ⁇ /-(demethyl)-3'- ⁇ /-( ⁇ -cyanoethyl)-3-O-decladinosyl-9-deoxo- 9a-methyl-9a-aza-9a-homoerythromycin A
  • Step 4 Preparation of 3'- ⁇ /-(demethyl)-3'- ⁇ /-( ⁇ -aminopropyl)-3-O-decladinosyl-9- deoxo-9a-methyl-9a-aza-9a-homoerythromycin A a'- ⁇ / ⁇ demethyO-a'- ⁇ / ⁇ -cyanoethyO-S-O-decladinosyl- ⁇ -deoxo- ⁇ a-methyl- ⁇ a-aza- ⁇ a- homoerythromycin A (0.6086 g, 0.97 mmol) was dissolved in glacial acetic acid (40 ml) and hydrogenated in a Parr reactor over PtO 2 (0.218 g) for 24 hours at 5.0 Barr.
  • Step 1 Preparation of 3-(7-Chloroquinolin-4-ylamino)propyl alcohol
  • Example 3 To a solution of 3'- ⁇ /-(demethyl)-3'- ⁇ /-( ⁇ -aminopropyl)-9-deoxo-9a-methyl-9a-aza-9a- homoerythromycin A (Intermediate 1) (0.5 g, 0.63 mmol) in DMSO (20 ml_), 4,7-dichloroquinoline (0.624 g, 3.15 mmol), NaHCO 3 (1 1 1 mg), and DIPEA (0.33 ml, 1.9 mmol) were added. The reaction mixture was heated at 1 10 0 C for 20 hours. The reaction mixture was evaporated to dryness. Crude residue was diluted with EtOAc (50 ml) and washed with water (50 ml) at pH 5.
  • Example 10 The analysis of NMR spectra of Example 9 showed two sets of resonance lines which both correspond to the structure shown. Difference in chemical shifts in those two sets suggests that they belong to two different conformers, their origin most probably being the slow rotation around CO-N bond.
  • Example 10 The analysis of NMR spectra of Example 9 showed two sets of resonance lines which both correspond to the structure shown. Difference in chemical shifts in those two sets suggests that they belong to two different conformers, their origin most probably being the slow rotation around CO-N bond.
  • Example 10 The analysis of NMR spectra of Example 10 showed two sets of resonance lines which both correspond to the structure shown. Difference in chemical shifts in those two sets suggests that they belong to two different rotamers. The amounts of rotamers are estimated to be 60 % and 40 %.
  • the in vitro potency of the compounds has been compared with that of azithromycin.
  • the compounds listed in Table 1 were profiled for their antimalarial activity against two different P. falciparum parasites (W2 and 3D7A) with different susceptibilities.
  • the IC 50 values of the tested compounds are provided as a range:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de 9-déoxo-9a-méthyl-9a-aza-9a-homoérythromycine A 3'-N-substituée ayant une activité antipaludique. Plus particulièrement, l'invention porte sur des dérivés de 9-déoxo-9a-méthyl-9a-aza-9a-homoérythromycine A 3'-N-substituée et de 3-O-décladinosyl-9-déoxo-9a-méthyl-9a-aza-9a-homoérythromycine A 3'-N-substituée ayant une activité antipaludique. L'invention concerne également les intermédiaires pour leur préparation, les procédés pour leur préparation, leur utilisation comme agents thérapeutiques et leurs sels ayant une activité antipaludique.
PCT/EP2010/050969 2009-01-30 2010-01-28 9-déoxo-9a-méthyl-9a-azahomoérythromycine 3'-n-substituée ayant une activité antipaludique WO2010086351A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14864009P 2009-01-30 2009-01-30
US61/148,640 2009-01-30

Publications (1)

Publication Number Publication Date
WO2010086351A1 true WO2010086351A1 (fr) 2010-08-05

Family

ID=41718959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/050969 WO2010086351A1 (fr) 2009-01-30 2010-01-28 9-déoxo-9a-méthyl-9a-azahomoérythromycine 3'-n-substituée ayant une activité antipaludique

Country Status (1)

Country Link
WO (1) WO2010086351A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021073303A (ja) * 2015-11-19 2021-05-13 エピエンド ファーマシューティカルズ イーエッチエフ． 上皮バリア機能増強特性を有するアジスロマイシン誘導体
WO2021204423A1 (fr) 2020-04-05 2021-10-14 University of Zagreb School of Medicine Utilisation d'azalides à 15 chaînons en tant que principes actifs dans le traitement d'infections virales

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1122261A2 (fr) * 2000-01-31 2001-08-08 Pfizer Products Inc. Macrolides antibactériennes à 13 ou 14 chainons
EP1253153A1 (fr) * 2001-04-27 2002-10-30 Pfizer Products Inc. Procédé de préparation de dérivés de 9-deoxo-9a-aza-9a-homoerythromycin A substitués en position 4''
WO2006120541A1 (fr) 2005-05-10 2006-11-16 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Macrolides a liaison ether convenant pour le traitement des infections microbiennes
WO2007054904A2 (fr) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Macrolides en tant qu’agents anti-inflammatoires
WO2007125414A2 (fr) * 2006-05-03 2007-11-08 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9a-azalides substitués
WO2009016142A1 (fr) * 2007-07-30 2009-02-05 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Dérivés de 9-désoxo-9a-méthyl-9a-aza-9a-homoérythromycine a et leurs utilisations pour le traitement de la malaria

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1122261A2 (fr) * 2000-01-31 2001-08-08 Pfizer Products Inc. Macrolides antibactériennes à 13 ou 14 chainons
EP1253153A1 (fr) * 2001-04-27 2002-10-30 Pfizer Products Inc. Procédé de préparation de dérivés de 9-deoxo-9a-aza-9a-homoerythromycin A substitués en position 4''
WO2006120541A1 (fr) 2005-05-10 2006-11-16 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Macrolides a liaison ether convenant pour le traitement des infections microbiennes
WO2007054904A2 (fr) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Macrolides en tant qu’agents anti-inflammatoires
WO2007125414A2 (fr) * 2006-05-03 2007-11-08 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9a-azalides substitués
WO2009016142A1 (fr) * 2007-07-30 2009-02-05 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Dérivés de 9-désoxo-9a-méthyl-9a-aza-9a-homoérythromycine a et leurs utilisations pour le traitement de la malaria

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
A.K. CHATTERJEE; T.-L. CHOI; D.P. SANDERS; R.H. GRUBBS, JACS, vol. 125, 2003, pages 11360
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
COLLECTION CZECH. CHEM. COMMUN., vol. 32, 1967, pages 3159
E.W. MARTIN: "Remington's Pharmaceutical Sciences"
GREEN; WUTS: "Protective Groups in Organic Synthesis.", 1999, JOHN WILEY AND SONS
J. CHEM. RES. (S), 1997, pages 152
J. MED. CHEM, vol. 51, 2008, pages 424 - 431
S. K. PURI; G. P. DUTI, CHEMOTHERAP, vol. 35, 1989, pages 187
S. K. PURI; N. SINGH, EXP. PARASITOL., vol. 94, 2000, pages 8
S. L. ANDERSON ET AL., ANN. INTERN. MED., vol. 123, 1995, pages 771
S. T. SADIQ ET AL., LANCET, vol. 346, 1995, pages 881
TETRAHEDRON LETT., vol. 12, 1971, pages 813 - 816
W. R. TAYLOR ET AL., CLIN. INFECT. DIS., vol. 28, 1999, pages 74

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021073303A (ja) * 2015-11-19 2021-05-13 エピエンド ファーマシューティカルズ イーエッチエフ． 上皮バリア機能増強特性を有するアジスロマイシン誘導体
US11236120B2 (en) * 2015-11-19 2022-02-01 Epiendo Pharmaceuticals Ehf Azithromycin derivatives with epithelial barrier enhancement properties
JP7256558B2 (ja) 2015-11-19 2023-04-12 エピエンド ファーマシューティカルズ イーエッチエフ． 上皮バリア機能増強特性を有するアジスロマイシン誘導体
WO2021204423A1 (fr) 2020-04-05 2021-10-14 University of Zagreb School of Medicine Utilisation d'azalides à 15 chaînons en tant que principes actifs dans le traitement d'infections virales

Similar Documents

Publication Publication Date Title
EP1841437B1 (fr) Azalides 9a-carbamoyle et thiocarbamoyle avec activite antipaludique
JP2017128605A (ja) 抗ウイルス化合物の固体形態
WO2006075256A2 (fr) 9a-carbamoyl-y-aminopropyl- et 9a-thiocarbamoyl-y-aminopropyl-azalides a activite anti-paludique
EA016813B1 (ru) Каннабиноидная фармацевтическая композиция и способы ее получения и введения
TW200817331A (en) Novel heterocyclic compounds
KR20170008893A (ko) 날메펜 히드로클로라이드 2수화물
BRPI0808378A2 (pt) Composto de 6-benzil-2,3,4,7-treta-hidro-indolo[2,3-c] quinolina úteis como inibidores de pde5
JPH0471077B2 (fr)
US20090036388A1 (en) Compounds
JP5437394B2 (ja) 抗炎症性マクロライド
US20140350099A1 (en) Method of Treating or Preventing Pain
ES2344518T3 (es) 9a-carbamoil-gamma-aminopropil- y 9a-tiocarbamoil-gamma-aminopropil-azalidos con actividad antimalarica.
US7863323B1 (en) Flavonols
WO2011131749A1 (fr) Nouveaux macrolides à 14 et 15 chaînons pour le traitement de maladies inflammatoires à dominance en neutrophiles
WO2010086351A1 (fr) 9-déoxo-9a-méthyl-9a-azahomoérythromycine 3'-n-substituée ayant une activité antipaludique
KR20150124848A (ko) 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도
US20090105301A1 (en) 9a-substituted azalides for the treatment of malaria
CN113214097A (zh) 治疗阿尔茨海默病的化合物
CN114190092B (zh) 3-去氧-2-酮糖酸含氮衍生物及其制备方法和用途
CN115043782B (zh) 4h-3,1-苯并噁嗪-4-酮衍生物及其制备方法和应用
US20230111856A1 (en) Opioid receptor antagonists
JPH09512254A (ja) 尿失禁を処置するためのキノロン誘導体
WO2007105551A1 (fr) nouveau derive de pyridine ayant une activite contre helicobacter pylori
WO2012032952A1 (fr) Composé ayant une activité antipaludique et médicament antipaludique
DK149769B (da) Analogifremgangsmaade til fremstilling af trans-4-(n-(substitueret-benzyliden)aminomethyl)-cyklohexan-1-carboxylsyre og derivater heraf

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10701863

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10701863

Country of ref document: EP

Kind code of ref document: A1